
Supplemental Table S1—Changes in myocardial glucose metabolic rate, insulin sensitivity and clinical and metabolic parameters after treatment for 26 weeks after first period

		Empag	diglozin		Glimepiride						
	n=12							Adjusted difference		P value	
	Before treatment	After 26 weeks treatment	Treatment difference	P value	Before treatment	After 26 weeks treatment	Treatment difference	P value	between groups (95% CI)		
BMI (Kg/m²)	30±3.4	28.8±4.4	-1.05±2.01	0.09	32.7±4.6	32.3±4.5	-0.39±0.7	0.1	-1.008	(-1.99, -0.02)	0.4
Waist circumference (cm)	105±8	103±8	-1.92±2.6	0.02	110±10	109.9±9	-0.36±1.8	0.5	-1.98	(-3.41, -0.56)	0.1
Systolic blood pressure (mmHg)	126±10	117±12	-8.16±11	0.03	130±15	133.8±14	3.63±8.9	0.2	-8.78	(-14.9, -2.65)	0.006
Diastolic blood pressure (mmHg)	79±10	77±6	-2.16±8.7	0.4	81±12	84.4±11	3.18±11.5	0.3	-2.72	(-7.43, 1.99)	0.06
Heart Rate (bpm)	75.4±8	69.5±8	-5.9±9.5	0.055	72.3±10	77.7±14	5.27±5.02	0.006	-5.71	(-10.43, -0.99)	0.004
Fasting Glucose (mg/dL)	155±30	128±22	-24.9±18	0.001	142±19	124.7±15	-20.3±24	0.01	-22.8	(-32.6, -12.97)	0.9
HbA1c (%/mmol/mol)	7.8±1 (62±7.6)	6.9±0.8 52±5.6	-0.85±0.7 -5.95±4.9	0.001	7.3±0.8 (56±5.9)	6.6±0.7 49±4.9	-0.65±0.8 -4.55±5.6	0.02	-0.74	(-1.08, 0.40)	0.9
Fasting β-hydroxybutyrate (mmol/l)	0.10±0	0.25±0.06	0.15±0.06	<0.0001	0.10±0	0.104±0.01	0.001 ±0.001	0.9	0.15	(0.12, 0.17)	<0.0001
Insulin-stimulated glucose disposal corrected for fat- free mass and urinary glucose loss (mg/min x Kg FFM)	3.65±2.4	6.18±3.8	2.53±4.1	0.07	4.08±2.5	3.36±1.7	-0.7±2.4	0.3	2.38	(0.50, 4.25)	0.03

Myocardial MrGlu	14.7±8	8.4±6	-6.36±6.2	0.007	13.5±12	15.4±10	1.99±5.8	0.3	-6.19	(-9.62, -2.75)	0.003
(µmol/min/100g)											

Data are means \pm SD, unless otherwise indicated and analyzed using ANCOVA adjusting for baseline. BMI=Body Mass Index. MrGlu: glucose metabolic rate

Supplemental Figure S1: Study design



Dynamic ¹⁸F-FDG-PET combined with euglycemic hyperinsulinemic damp Ecocardiography Clinical, anthropometric and laboratory evaluation Dynamic ¹⁸F-FDG-PET combined with euglycemic hyperinsulinemic damp Ecocardiography Clinical, anthropometric and laboratory evaluation Dynamic ¹⁸F-FDG-PET combined with euglycemic hyperinsulinemic damp Ecocardiography
Clinical, anthropometric and laboratory evaluation

